Noble Capital Markets Initiates Coverage On Eledon Pharma with Outperform Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Noble Capital Markets analyst Robert LeBoyer has initiated coverage on Eledon Pharma (NASDAQ:ELDN) with an Outperform rating and a price target of $10.

September 27, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eledon Pharma has been given an Outperform rating by Noble Capital Markets, with a price target of $10.
The Outperform rating from Noble Capital Markets indicates a positive outlook for Eledon Pharma. The price target of $10 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100